Double trouble: IRAK1/4 inhibitors in AML/MDS

被引：0
|
作者：
Uckelmann, Hannah J. [1 ,2 ,3 ]
Klusmann, Jan-Henning [1 ,2 ,3 ]
机构：
[1] Goethe Univ Frankfurt, Frankfurt, Germany
[2] Frankfurt Canc Inst, Frankfurt, Germany
[3] German Canc Consortium, Dresden, Germany
来源：
BLOOD | 2023年 / 142卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：945 / 946
页数：2
相关论文
共 50 条
  • [1] IRAK1: oncotarget in MDS and AML
    Beverly, Levi J.
    Starczynowski, Daniel T.
    ONCOTARGET, 2014, 5 (07) : 1699 - 1700
  • [2] IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
    Bennett, Josh
    Yeung, Jennifer
    Sampson, Avery
    Hueneman, Kathleen
    Wunderlich, Mark
    Choi, Kwangmin
    Volk, Andrew
    Hoyt, Scott B.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2022, 140 : 2240 - 2241
  • [3] Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML
    Bennett, Joshua
    Ishikawa, Chiharu
    Agarwal, Puneet
    Yeung, Jennifer
    Sampson, Avery
    Uible, Emma
    Vick, Eric
    Bolanos, Lyndsey C.
    Hueneman, Kathleen
    Wunderlich, Mark
    Kolt, Amal
    Choi, Kwangmin
    Volk, Andrew
    Greis, Kenneth D.
    Rosenbaum, Jan
    Hoyt, Scott B.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2023, 142 (11) : 989 - 1007
  • [4] Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML
    Rosenbaum, Jan S.
    Hoyt, Scott B.
    Kolt, Amal S.
    Luedtke, Daniel A.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2022, 140 : 5949 - 5950
  • [5] Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
    Yosuke Tanaka
    Reina Takeda
    Tsuyoshi Fukushima
    Keiko Mikami
    Shun Tsuchiya
    Moe Tamura
    Keito Adachi
    Terumasa Umemoto
    Shuhei Asada
    Naoki Watanabe
    Soji Morishita
    Misa Imai
    Masayoshi Nagata
    Marito Araki
    Hitoshi Takizawa
    Tomofusa Fukuyama
    Chrystelle Lamagna
    Esteban S. Masuda
    Ryoji Ito
    Susumu Goyama
    Norio Komatsu
    Tomoiku Takaku
    Toshio Kitamura
    Nature Communications, 13
  • [6] Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
    Tanaka, Yosuke
    Takeda, Reina
    Fukushima, Tsuyoshi
    Mikami, Keiko
    Tsuchiya, Shun
    Tamura, Moe
    Adachi, Keito
    Umemoto, Terumasa
    Asada, Shuhei
    Watanabe, Naoki
    Morishita, Soji
    Imai, Misa
    Nagata, Masayoshi
    Araki, Marito
    Takizawa, Hitoshi
    Fukuyama, Tomofusa
    Lamagna, Chrystelle
    Masuda, Esteban S.
    Ito, Ryoji
    Goyama, Susumu
    Komatsu, Norio
    Takaku, Tomoiku
    Kitamura, Toshio
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] Targeting IRAK1 /IRAK4 Signaling in Waldenstrom's Macroglobulinemia
    Yang, Guang
    Liu, Xia
    Chen, Jie
    Xu, Lian
    Tsakmaklis, Nicholas
    Chen, Jiaji
    Patterson, Christopher J.
    Castillo, Jorge J.
    Cohen, Philip
    Tan, Li
    Buhrlage, Sara
    Gray, Nathanael
    Treon, Steven P.
    BLOOD, 2015, 126 (23)
  • [8] IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
    Bennett, Joshua
    Starczynowski, Daniel T.
    CURRENT OPINION IN HEMATOLOGY, 2022, 29 (01) : 8 - +
  • [9] Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients
    Rosenbaum, Jan S.
    Kolt, Amal S.
    Hoyt, Scott B.
    Hayes, Gregory M.
    Soldo, Brandi L.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2023, 142
  • [10] Characterization of Pellino2, a substrate of IRAK1 and IRAK4
    Strelow, A
    Kollewe, C
    Wesche, H
    FEBS LETTERS, 2003, 547 (1-3) : 157 - 161
12345